Hamburg Trumpets Potential Rewards Of Quality Improvement For Generic Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner takes a softer tone in repeating the message that quality must improve in the generics industry, saying the reward may manifest in inspection policy.
You may also be interested in...
FDA “Broad Agency Announcement” To Fund Generic, Clinical Design Research
Agency expects to provide $200,000 to $50 million on a wide range of research proposals to support regulatory science and innovation.
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says
“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.